Disease, Disability, and Injury Prevention and Control, 4752 [E9-1690]

Download as PDF 4752 Federal Register / Vol. 74, No. 16 / Tuesday, January 27, 2009 / Notices DEPARTMENT OF HEALTH AND HUMAN SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Centers for Disease Control and Prevention [Docket Number NIOSH–144] Disease, Disability, and Injury Prevention and Control mstockstill on PROD1PC66 with NOTICES6 Special Emphasis Panel (SEP): Autism Therapy Evaluation Effects of Hyperbaric Oxygen Therapy on Children with Autism, Request For Application (RFA), DD8EM–801. In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting: Time and Date: 1:30 p.m.–3 p.m., January 29, 2009 (Closed). Place: Teleconference. Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c) (4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92– 463. Matters To Be Discussed: The meeting will include the review, discussion, and evaluation of an application received in response to ‘‘Autism Therapy Evaluation Effects of Hyperbaric Oxygen Therapy on Children with Autism, RFA DD8EM–801.’’ This Federal Register notice is being published less than fifteen days prior to the meeting date, due to the decision of the National Center for Chronic Disease Prevention and Health Promotion to allow a deliberative discussion on this application. Contact Person for More Information: Brenda Colley Gilbert, Ph.D., Scientific Review Administrator, 2877 Brandywine Road, Atlanta, Georgia 30341, telephone: (770) 488–8390. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry. Lorenzo J. Falgiano, Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. E9–1690 Filed 1–26–09; 8:45 am] BILLING CODE 4163–18–P VerDate Nov<24>2008 17:20 Jan 26, 2009 Jkt 217001 Notice of Request for Public To Submit Comments; Extension of Comment Period AGENCY: National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: Extension of public comment period. SUMMARY: The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC) announced the availability of a draft document available for public comment entitled ‘‘NIOSH Criteria Document Update: Occupational Exposure to Hexavalent Chromium’’ on October 17, 2008, as well as a public meeting to be held on January 22, 2009. The document and instructions for submitting comments can be found at https:// www.cdc.gov/niosh/review/public/144/. Comments were to be provided to the NIOSH docket by January 31, 2009, as well as given orally at the public meeting. A request has been received to extend the comment period to permit the public more time to gather and submit information. Accordingly, NIOSH is extending the public comment period by 60 days to March 31, 2009. DATES: Written comments to NIOSH must be sent or postmarked by March 31, 2009. The public meeting will still take place on January 22, 2009, at Robert A. Taft Laboratories, Taft Auditorium, NIOSH, CDC, 4676 Columbia Parkway, Cincinnati, OH 45226–1998. Status: The public meeting will include scientists and representatives from various government agencies, industry, labor, and other stakeholders, and is open to the public, limited only by the space available. The meeting room accommodates 80 people. Persons wanting to attend or provide oral comments at the meeting were requested to notify the NIOSH Docket Office no later than January 7, 2009, at (513) 533–8611 or by e-mail at nioshdocket@cdc.gov. Persons wanting to provide oral comments will be permitted up to 20 minutes. If additional time becomes available, presenters will be notified. Oral comments given at the meeting PO 00000 Frm 00022 Fmt 4703 Sfmt 4703 must also be submitted to the docket in writing in order to be considered by the Agency. Written comments will also be accepted at the meeting. Written comments may also be submitted to the NIOSH Docket Office, Robert A. Taft Laboratories, 4676 Columbia Parkway, MS–C34, Cincinnati, Ohio 45226, telephone (513) 533–8611. All material submitted to the Agency should reference docket number NIOSH–144 and must be submitted by March 31, 2009, to be considered by the Agency. All electronic comments should be formatted as Microsoft Word. Please make reference to docket number NIOSH–144. All information received in response to this notice will be available for public examination and copying at the NIOSH Docket Office, Room 111, 4676 Columbia Parkway, Cincinnati, Ohio 45226. CONTACT PERSONS FOR TECHNICAL INFORMATION: Kathleen MacMahon, DVM; (513) 533–8547; MS–C32, Robert A. Taft Laboratories, 4676 Columbia Parkway, Cincinnati, OH, 45226–1998. Dated: January 16, 2009. James D. Seligman, Chief Information Officer, Centers for Disease Control and Prevention. [FR Doc. E9–1694 Filed 1–26–09; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Child Health and Human Development Special Emphasis Panel; Pediatric Functional Neuroimaging Study. Date: January 29, 2009. E:\FR\FM\27JAN1.SGM 27JAN1

Agencies

[Federal Register Volume 74, Number 16 (Tuesday, January 27, 2009)]
[Notices]
[Page 4752]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-1690]



[[Page 4752]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Disease, Disability, and Injury Prevention and Control

    Special Emphasis Panel (SEP): Autism Therapy Evaluation Effects of 
Hyperbaric Oxygen Therapy on Children with Autism, Request For 
Application (RFA), DD8EM-801.
    In accordance with Section 10(a)(2) of the Federal Advisory 
Committee Act (Pub. L. 92-463), the Centers for Disease Control and 
Prevention (CDC) announces the aforementioned meeting:
    Time and Date: 1:30 p.m.-3 p.m., January 29, 2009 (Closed).
    Place: Teleconference.
    Status: The meeting will be closed to the public in accordance with 
provisions set forth in Section 552b(c) (4) and (6), Title 5 U.S.C., 
and the Determination of the Director, Management Analysis and Services 
Office, CDC, pursuant to Public Law 92-463.
    Matters To Be Discussed: The meeting will include the review, 
discussion, and evaluation of an application received in response to 
``Autism Therapy Evaluation Effects of Hyperbaric Oxygen Therapy on 
Children with Autism, RFA DD8EM-801.''
    This Federal Register notice is being published less than fifteen 
days prior to the meeting date, due to the decision of the National 
Center for Chronic Disease Prevention and Health Promotion to allow a 
deliberative discussion on this application.
    Contact Person for More Information: Brenda Colley Gilbert, Ph.D., 
Scientific Review Administrator, 2877 Brandywine Road, Atlanta, Georgia 
30341, telephone: (770) 488-8390.
    The Director, Management Analysis and Services Office, has been 
delegated the authority to sign Federal Register notices pertaining to 
announcements of meetings and other committee management activities, 
for both CDC and the Agency for Toxic Substances and Disease Registry.

Lorenzo J. Falgiano,
Acting Director, Management Analysis and Services Office, Centers for 
Disease Control and Prevention.
[FR Doc. E9-1690 Filed 1-26-09; 8:45 am]
BILLING CODE 4163-18-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.